Agenus Inc.
AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulā¦ read more
Healthcare
Biotechnology
26 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.50
Price-5.18%
-$0.41
1Y
Price
Market Cap
$312.318m
Small
Price/Earnings 3y Avg5y Avg
3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+265.0%
EBITDA Margin+211.4%
Net Profit Margin-48.7%
Free Cash Flow Margin+265.0%
EBITDA Margin+211.4%
Net Profit Margin-48.7%
Free Cash Flow MarginRevenue
$123.866m
+3.3%
1y CAGR+9.6%
3y CAGR-9.5%
5y CAGREarnings
$64.607m
+84.5%
1y CAGR+26.8%
3y CAGR-184.8%
5y CAGREPS
$1.66
+79.9%
1y CAGR+38.3%
3y CAGR-131.6%
5y CAGRBook Value
-$227.983m
$186.456m
Assets$414.439m
Liabilities$304.464m
DebtDebt to Assets
163.3%
1.4x
Debt to EBITDAFree Cash Flow
-$87.528m
+43.8%
1y CAGR+24.5%
3y CAGR-197.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company